Clinical trials for autism

Discuss autism diets and biomedical treatments of autism.

Moderator: ModeratorBill

FatherOf2
Posts: 1587
Joined: Mon Mar 11, 2013 1:37 am

Clinical trials for autism

Postby FatherOf2 » Sat Jul 15, 2017 12:32 pm

It is interesting to see what researchers are up to: https://clinicaltrials.gov/ct2/results?cond=Autism&term=&cntry1=&state1=&SearchRecruiting=Find+a+study+to+participate+in&recrs=a

Here are some interesting trials:

Treatment With Acetyl-Choline Esterase Inhibitors in Children With Autism Spectrum Disorders, NCT01098383, Sheba Medical Center (Israel), 10 Years to 18 Years. I tried Galantamine, which is also acetylcholine esterase Inhibitor. It helped a lot, but the effect was transient.

Transcranial Direct Current Stimulation and Autism, NCT01603225, Johns Hopkins University, 14 Years to 79 Years. Wow! An Eastern European treatment of autism is finally getting to USA! And not just some wellness center, but John Hopkins University!

Pilot Trial of Pregnenolone in Autism, NCT02627508, Stanford University, 14 Years to 21 Years. Pregnenolone is a naturally occurring steroid hormone in the brain that has been implicated in treating various psychiatric conditions. The investigators hope to learn the effects and safety of using pregnenolone in reducing irritability and sensitivity to sensory differences and improving social communication in individuals with autism.

Trial of Propranolol in Children and Youth With Autism Spectrum Disorder and Predictors of Response, NCT02871349, University of Missouri-Columbia, 7 Years to 24 Years, The hypothesis is that social functioning and language abilities will benefit from serial doses of propranolol, and that those with the greatest degree of autonomic dysregulation, or the lowest functional connectivity, will demonstrate the greatest benefit from the drug. -------- I use Propranolol for my anxiety but only before a public speech event, and it works great! No drowsiness!

A Pilot Treatment Study of Insulin-Like Growth Factor-1 (IGF-1) in Autism Spectrum Disorder, NCT01970345, Icahn School of Medicine at Mount Sinai, 5 Years to 12 Years, IGF-1 is an FDA approved, commercially available compound that crosses the blood-brain barrier and has beneficial effects on synaptic development by promoting neuronal cell survival, synaptic maturation, and synaptic plasticity. ------- this is probably the most interesting trial worth looking into further

Autism Oxytocin Brain Project, NCT03033784, Emory University, 18 Years to 45 Years, Oxitocin again!

The Role of Vasopressin in the Social Deficits of Autism, NCT01962870, Stanford University, 6 Years to 12 Years, Vasopressin is closely related to oxytocin, which is currently being tested as a treatment for autism, and has been shown to enhance social functioning in animals. -------- my psychiatrist mentioned this trial and wants my son to aprticipate

Transcranial Magnetic Stimulation (rTMS) and Autism. (TMSAUTISME), NCT01648868, Assistance Publique - Hôpitaux de Paris, 18 Years to 30 Years, those in France should try it, I heard good things about rTMS.

Study of Intranasal Ketamine for Social Impairment in Autism Spectrum Disorder, NCT02611921, Children's Hospital Medical Center, Cincinnati, 12 Years to 30 Years, Ketamine, sold under the brand name Ketalar among others, is a medication mainly used for starting and maintaining anesthesia. It induces a trance-like state while providing pain relief, sedation, and memory loss -------- Are they serious?

A Trial of Sertraline in Young Children With Autism Spectrum Disorder, NCT02385799, University of California, Davis, 2 years to 6 years, Sertraline (Zoloft), an anti-depressant typically used in the treatment of depression, obsessive-compulsive disorder, panic disorder, and other conditions. The researchers are investigating the use of this selective serotonin reuptake inhibitor (SSRI) in ASD because a retrospective study has shown significant improvements in language and social deficits. There is also emerging evidence regarding the stimulation of brain-derived neurotrophic factor (BDNF) and the stimulation of neurogenesis when an SSRI is given early on in the development of animal models of Down syndrome. The researchers hope to see improvements in language stimulation, social gaze and social reciprocity, spatial attention, and a decrease in autistic behaviors. --------- this study is also very interesting and worth looking into!

Sulforaphane in a New Jersey (NJ) Population of Individuals With Autism, NCT02677051, Rutgers, The State University of New Jersey, 13 Years to 30 Years --------- those in NJ should take advantage of this study

Predicting Treatment Response to Memantine in Autism Using Magnetic Resonance Spectroscopy, NCT02811627, University of Missouri-Columbia, 16 Years and older, Memantine, an NMDA receptor antagonist, has been explored as a possible therapeutic agent that reduces the excitatory (glutamate) - inhibitory (gamma amino-butyric acid, GABA) imbalance in autism pathology and improves social and communication deficits.

Behavioral and Neural Response to Memantine in Adolescents With Autism Spectrum Disorder, NCT01972074, Massachusetts General Hospital, 8 Years to 17 Years, Investigators hypothesize that following memantine therapy, ASD subjects will exhibit a decrease in glutamate (Glu) concentration in the anterior-cingulate cortex (ACC) and a change towards normalization in altered functional connectivity of the ACC and medial temporal lobes, consistent with improvement in social impairments in ASD.

A 12-weeks Study to Evaluate Sulforaphane in Treatment of Autism Spectrum Disorder, NCT02879110, Central South University, 10 Years to 15 Years

Measuring Brain Inflammation in Autism, NCT03117530, University of California, Los Angeles, 18 Years to 35 Years, Emerging evidence indicates that levels of brain inflammation are increased in ASD. In particular, recent work implicates hyperactivity of microglial cells, the resident immune cells of the brain. This study will measure microglial activation in ASD using positron emission tomography (PET) brain imaging. Subjects with ASD will then undergo 12-week open label treatment with minocycline, an FDA-approved antibiotic thought to block microglial activation. ------- very interesting! I suspect that my son has microglial activation because he reacted so well to Quercetin.

Sulforaphane Treatment of Children With Autism Spectrum Disorder (ASD), NCT02561481, University of Massachusetts, Worcester, 3 Years to 12 Years

Study of Acamprosate in Autism, NCT01813318, Children's Hospital Medical Center, Cincinnati, 5 Years to 17 Years, Acamprosate is a medication used to treat alcohol dependence. The mechanism of action of acamprosate is unknown and controversial. At high concentrations, well above those that occur clinically, reports of inhibition of glutamate receptor-activated responses, enhancement of NMDA receptor function, weak antagonization of the NMDA receptor, partial agonism of the polyamine site of the NMDA receptor, and possible inhibition of the mGluR1 and mGluR5 have all been published. However, no direct action of acamprosate at clinically-relevant concentrations has yet been reported. Moreover, a subsequent study found no action of acamprosate on the mGluR1 or mGluR5 at concentrations as high as 100 μM, nor at GABAA or glycine receptors or voltage-gated sodium channels

An Open-Label Trial of Buspirone for the Treatment of Anxiety in Youth With Autism Spectrum Disorders, NCT01850355, Massachusetts General Hospital, 6 Years to 17 Years

Nicotinic Cholinergic Modulation as a Novel Treatment Strategy for Aggression Associated With Autism, NCT02552147, Yale University, 18 Years to 40 Years, The purpose of this pilot study is to test whether transdermal nicotine is effective for irritability and/or aggression in adults with ASD

FatherOf2
Posts: 1587
Joined: Mon Mar 11, 2013 1:37 am

Re: Clinical trials for autism

Postby FatherOf2 » Sat Jul 15, 2017 1:20 pm

Summary: Several studies are investigating Oxitocin, Sulforaphane, and Memantine. One study is investigating Vasopressin, which is related to Oxytocin. A couple of studies investigate AcCh esterase inhibitor Donepezil. A couple of studies are looking at TMS, which is magnetic therapy reported by some parents to help a lot. One study is looking at Transcranial Direct Current Stimulation (TDCS), which is a standard treatment of Autism in Eastern Eurpoean countries like Russia. And this study is done by John Hopkins University, the premier medical establishment in USA. One study is investigating Insulin-Like Growth Factor 1 (IGF-1), a hormone that is similar in structure to insulin and works with Growth Hormone to reproduce and regenerate cells. It also reduces inflammation. One study is investigating Zoloft, which stimualtes brain-derived neurotrophic factor (BDNF) and neurogenesis. One study investigates minocycline to reduce mast cell activation.

FatherOf2
Posts: 1587
Joined: Mon Mar 11, 2013 1:37 am

Re: Clinical trials for autism

Postby FatherOf2 » Sat Jul 15, 2017 3:56 pm

Upcoming (not recruiting yet) studies:

A Study of Bumetanide for the Treatment of Autism Spectrum Disorders, NCT03156153, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, 3 Years to 6 Years, 0.5mg 2x/day ---- strongly recommend those in Shanghai to take advantage of this study. Bumetanide is part of my son's protocol.

A Feasibility Study of N-acetylcysteine for Self-injurious Behavior in Children With Autism Spectrum Disorder (NAC), NCT03008889, Emory University, 5 Years to 12 Years,

Cannabidivarin (CBDV) vs. Placebo in Children With Autism Spectrum Disorder (ASD), NCT03202303, Montefiore Medical Center, 5 Years to 18 Years, Cannabidivarin (CBDV) is a non-psychoactive cannabinoid found in Cannabis with anti-epileptic and anti-convulsive action.

FatherOf2
Posts: 1587
Joined: Mon Mar 11, 2013 1:37 am

Re: Clinical trials for autism

Postby FatherOf2 » Sat Jul 15, 2017 4:41 pm

Studies for ADHD (just summary):
RECRUITING:
- Vyvanse (Lisdexamfetamine)
- Vyvanse (Lisdexamfetamine) vs Tennex (Guanfacine)
- Equazen Eye Q (500mg/day = 116 mg DHA, 372 mg EPA, 40 mg GLA)
- Ritalin IR
- Strattera (Atomoxetine)
- Nicotine nasal spray
- Amiloride Hydrochloride (diuretic)
- Rhodiola Rosea (herb)
- L. helveticus R0052 and B. longum R0175 (probiotics)
- Vayarin
- Adderall-XR
- Tipepidine Hibenzate
- Celexa

UPCOMING:
- Pycnagenol (< 30 kg body weight: 20 mg Pycnogenol/day Subjects >= 30 kg body weight: 40 mg Pycnogenol/day) - useless in my opinion
- tDCS
- Calanus oil (omega 3 from zooplankton Calanus finnmarchicus that has a high natural content of steardidonic acid 18:3 n-3 that is a precursor to EPA. The oil also has a high content of astaxanthines). Stearidonic acid may be a cofactor to help improve absorption of DHA and other omega-3s. Krill oil also contains stearidonic acid but in smaller quantities.

Interestingly, US military is conducting a study of Krill Oil effect on soldier's cognition:
https://www.army.mil/article/172714/omega_3_study_aims_to_give_soldiers_a_cognitive_advantage
"We're assessing cognitive processes. Specifically, we are studying concepts such as decision-making and attention and impulsivity, and we're doing this with computer-based cognitive tests ... For anyone who volunteers to be in the study, they have a fifty-fifty chance of being in the placebo or the experimental group. Everybody gets capsules. Some of the capsules have macadamia nut oil in them and others have krill oil in them. The krill oil is very high in omega-3s. Macadamia nut oil has no omega-3s"


Return to “Diet and Biomedical Treatments for Autism”